CompoAtlas

Herbolax

En vente sur le marché américain (selon le DSLD)

Genestra Brands, food supplement from the US market

Herbolax (Genestra Brands), a food supplement au code-barres 883196151707, is described by its US market label. If sold in France, it would be subject to 3 points of French or European regulation, detailed below. The formula sold in Europe under the same name may differ.

Official label. Dietary Supplement Label Database (DSLD), US National Institutes of Health: current and off-market labels, retrieved 27 October 2026.

Source: NIH Office of Dietary Supplements, Dietary Supplement Label Database (CC0); US market labels.

Displayed label: Official label. Labels on the market are prioritised, followed by the most recent for the same status.

If this product were sold in France

A daily dose is calculated only if the label gives the maximum number of servings and a unit of mass (or international units for vitamin D). Quantities come from the label, not an analysis. In the United States, the label presents this product as a ‘dietary supplement’; in France, a product of this type may belong to another category (a sports powder, for example), and maximum food supplement doses do not apply to it.

Label composition

Brand
Genestra Brands
Barcode
883196151707
Form
Capsule
One serving
3 capsules
Servings
up to 1 serving per day
Other ingredients (in English, as written)
Cellulose, Hypromellose, Silica, Hyprolose, Magnesium Stearate
Ingredient (as written, in English)CategoryPer serving
Senna (Senna alexandrina)Plant840 mg
Chinese RhubarbPlant195 mg
AnisePlant165 mg
Fenugreek (Trigonella foenum-graecum)Plant165 mg
Cascara Sagrada (Frangula purshiana)Plant67.5 mg

Other versions of this label

The differences below describe each other version relative to the label shown on this page. They concern active ingredient rows and quantities per serving as written. Missing quantities are not estimated and different units are not converted. Dates refer to entry into DSLD, not necessarily to a formula change.

This information reproduces the US label recorded by the US National Institutes of Health (NIH). It does not say whether the product is effective and does not replace advice from a doctor or pharmacist, particularly during pregnancy or when taking medication.

Official warnings (Health Canada)

Health Canada publishes warnings on these ingredients:

  • Senna
    Read the warning, when it applies and the studies cited

    SENNA - SENNA ALEXANDRINA

    Route of administration: Oral

    Cautions and warnings

    Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you have a kidney disorder or a lazy bowel (EMA 2018a,b; Brinker 2010; Blumenthal et al. 2000; WHO 1999).

    4 studies cited in the text have no matching reference in the monograph (see the anomalies listed on the sources page).

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are taking heart medications, corticosteroids, diuretics, or other health products that may contribute to electrolyte imbalance (EMA 2018a,b; Brinker 2010; Blumenthal et al. 2000; WHO 1999).

    4 studies cited in the text have no matching reference in the monograph (see the anomalies listed on the sources page).

    Contraindications

    Do not use if you are pregnant or breastfeeding (EMA 2018a,b; Brinker 2010; Blumenthal et al. 2000).

    3 studies cited in the text have no matching reference in the monograph (see the anomalies listed on the sources page).

    Do not use if you have inflammatory bowel disease, fever or any undiagnosed gastrointestinal trouble (EMA 2018a,b; Gardner and McGuffin 2013; Brinker 2010; WHO 1999).

    4 studies cited in the text have no matching reference in the monograph (see the anomalies listed on the sources page).

    Known adverse reactions

    Stop use if hypersensitivity/allergy or diarrhoea occurs (EMA 2018a,b; Blumenthal et al. 2000; WHO 1999).

    3 studies cited in the text have no matching reference in the monograph (see the anomalies listed on the sources page).

    Health Canada monograph dated 26 July 2024

  • Fenugreek
    Read the warning, when it applies and the studies cited

    FENUGREEK - TRIGONELLA FOENUM-GRAECUM - Oral

    Cautions and warnings

    Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are pregnant (Gardner and McGuffin 2013; Brinker 2010; Mills et al. 2006; Hoffman 2003; Blumenthal et al. 2000).

    5 studies cited in the text have no matching reference in the monograph (see the anomalies listed on the sources page).

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you have diabetes (Brinker 2010; Mills and Bone 2005).

    2 studies cited in the text have no matching reference in the monograph (see the anomalies listed on the sources page).

    Health Canada monograph dated 29 May 2026

    FENUGREEK - TRIGONELLA FOENUM-GRAECUM - Topical

    Cautions and warnings

    Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.

    Health Canada monograph dated 29 May 2026

  • Cascara Sagrada
    Read the warning, when it applies and the studies cited

    CASCARA SAGRADA - FRANGULA PURSHIANA

    Route of administration: Oral

    Cautions and warnings

    Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you have a kidney disorder or a lazy bowel (EMA 2020; Brinker 2010; WHO 2002).

    3 studies cited in the text have no matching reference in the monograph (see the anomalies listed on the sources page).

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are taking heart medications, corticosteroids, diuretics, or other health products that may contribute to electrolyte imbalance (EMA 2020; Brinker 2010; WHO 2002; Blumenthal et al. 2000).

    4 studies cited in the text have no matching reference in the monograph (see the anomalies listed on the sources page).

    Contraindications

    Do not use if you are pregnant or breastfeeding (EMA 2020; Brinker 2010; Blumenthal et al. 2000).

    3 studies cited in the text have no matching reference in the monograph (see the anomalies listed on the sources page).

    Do not use if you have inflammatory bowel disease, fever or any undiagnosed gastrointestinal trouble (EMA 2020; Brinker 2010; WHO 2002).

    3 studies cited in the text have no matching reference in the monograph (see the anomalies listed on the sources page).

    Known adverse reactions

    Stop use if hypersensitivity/allergy or diarrhea occurs (EMA 2020; Brinker 2010).

    2 studies cited in the text have no matching reference in the monograph (see the anomalies listed on the sources page).

    Health Canada monograph dated 30 May 2025

They concern the ingredient, not this product or its dose. They do not replace medical advice.

List declared on (register: Dietary Supplement Label Database (DSLD), US National Institutes of Health: current and off-market labels).

Photograph the packaging

Brand : Genestra Brands

Is something on this product wrong or out of date, whether you are a reader or the brand? Write to contact@compoatlas.com: every correction is published in the corrections log.

List recorded in 2022. Photograph the packaging to check whether it has changed.

Enter to analyse, Shift+Enter for a new line